Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to chemotherapy in stable advanced lung adenocarcinoma
NCT03240549Phase 2Unknown
- Sponsor
- Beijing Hospital
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of bevacizumab in lung adenocarcinoma (2 arms), sponsored by Beijing Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03240549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240549.